Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon


Mordmuller, B; Szywon, K; Greutelaers, B; Esen, M; Mewono, L; Treut, C; Murbeth, RE; Chilengi, R; Noor, R; Kilama, WL; Imoukhuede, EB; Imbault, N; Leroy, O; Theisen, M; Jepsen, S; Milligan, P; Fendel, R; Kremsner, PG; Issifou, S; (2010) Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. Vaccine, 28 (41). pp. 6698-6703. ISSN 0264-410X DOI: 10.1016/j.vaccine.2010.07.085

Full text not available from this repository.

Abstract

Malaria is still one of the major public health threats in sub-Saharan Africa. An effective vaccine could be a sustainable control measure that can be integrated into existing health infrastructures. The malaria vaccine candidate GMZ2 is a recombinant fusion protein of conserved parts of Plasmodium falciparum Glutamate Rich Protein and Merozoite Surface Protein 3 adjuvanted with aluminium hydroxide. GMZ2 is immunogenic and well tolerated in malaria-naive adults from Germany. To assess safety and immunogenicity in malaria-exposed individuals, 40 adults from Lambarene. Gabon were randomly assigned to receive either 100 p,g GMZ2 or a rabies control vaccine three times in monthly intervals. Both vaccines were well tolerated. One month after a full course of vaccination, GMZ2-vaccinated individuals had 1.4-fold (95% confidence interval: [1.1, 1.7]) higher baseline-corrected anti-GMZ2 antibody levels and more GMZ2-specific memory B-cells compared to the rabies group (p=0.039), despite a high prevalence of GMZ2-specific immune reactivity due to previous intense exposure to P. falciparum. (C) 2010 Elsevier Ltd. All rights reserved.

Item Type: Article
Keywords: Malaria vaccine, Phase I clinical trial, Malaria immunity, MEROZOITE SURFACE PROTEIN-3, GLUTAMATE-RICH PROTEIN, PLASMODIUM-FALCIPARUM, PROTECTION, ASSOCIATION, ANTIBODIES, CHILDREN, GLURP
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology
Research Centre: Tropical Epidemiology Group
Vaccine Centre
PubMed ID: 20696154
Web of Science ID: 282734800007
URI: http://researchonline.lshtm.ac.uk/id/eprint/2357

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
317Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item